European Medicines Agency

Doc. Ref. EMEA/161203/2009
P/60/2009

EUROPEAN MEDICINES AGENCY DECISION

of 27 March 2009

on the agreement of a Paediatric Investigation Plan and on the granting of a deferral and on the granting of a waiver for nilotinib (Tasigna) (EMEA-000290-PIP01-08) in accordance with Regulation (EC) No 1901/2006 of the European Parliament and of the Council as amended

(ONLY THE ENGLISH TEXT IS AUTHENTIC)

DISCLAIMER: This Decision does not entitle to the rewards and incentives referred to in Title V of Regulation (EC) No 1901/2006, as amended.

7 Westferry Circus, Canary Wharf, London, E14 4HB, UK
Tel. (44-20) 74 18 84 00 Fax (44-20) 74 18 86 70
E-mail: mail@emea.europa.eu http://www.emea.europa.eu

EUROPEAN MEDICINES AGENCY DECISION

of 27 March 2009

on the agreement of a Paediatric Investigation Plan and on the granting of a deferral and on the granting of a waiver for nilotinib (Tasigna) (EMEA-000290-PIP01-08) in accordance with Regulation (EC) No 1901/2006 of the European Parliament and of the Council as amended

THE EUROPEAN MEDICINES AGENCY,

Having regard to the Treaty establishing the European Community,

Having regard to Regulation (EC) No 1901/2006 of the European Parliament and of the Council of 12 December 2006 on medicinal products for paediatric use as amended and amending Regulation (EEC) No. 1768/92, Directive 2001/20/EC, Directive 2001/83/EC and Regulation (EC) No 726/2004[1],

Having regard to Regulation (EC) No 726/2004 of the European Parliament and of the Council of 31 March 2004 laying down Community procedures for the authorisation and supervision of medicinal products for human and veterinary use and establishing a European Medicines Agency[2],

Having regard to the application submitted by Novartis Europharm Limited on 27 May 2008 under Article 16(1) also requesting a waiver under Article 13 of said Regulation and a deferral under Article 20 of said Regulation,

Having regard to the Opinion of the Paediatric Committee of the European Medicines Agency, issued on 6 February 2009, in accordance with Article 18 of Regulation (EC) No 1901/2006 as amended, and Article 13 of said Regulation and Article 21 of said Regulation,

Having regard to Article 25 of Regulation (EC) No 1901/2006 as amended,

WHEREAS:

(1) The Paediatric Committee of the European Medicines Agency has given an opinion on the agreement of a Paediatric Investigation Plan and on the granting of a deferral and on the granting of a waiver,

(2) It is therefore appropriate to adopt a Decision granting a Paediatric Investigation Plan.

(3) It is therefore appropriate to adopt a Decision granting a deferral.

(4) It is therefore appropriate to adopt a Decision granting a waiver.

[1] OJ L 378, 27.12.2006, p.1
[2] OJ L 136, 30.4.2004, p. 1

HAS ADOPTED THIS DECISION:

Article 1

A Paediatric Investigation Plan for nilotinib (Tasigna), hard capsule, oral use, the details of which are set out in the Opinion of the Paediatric Committee of the European Medicines Agency annexed hereto, together with its appendices, is hereby agreed.

Article 2

A deferral for nilotinib (Tasigna), hard capsule, oral use, the details of which are set out in the Opinion of the Paediatric Committee of the European Medicines Agency annexed hereto, together with its appendices, is hereby granted.

Article 3

A waiver for nilotinib (Tasigna), hard capsule, oral use, the details of which are set out in the Opinion of the Paediatric Committee of the European Medicines Agency annexed hereto, together with its appendices, is hereby granted.

Article 4

This decision is addressed to Novartis Europharm Limited, Wimblehurst Road, RH12 5AB Horsham, United Kingdom.

Done at London, 27 March 2009

For the European Medicines Agency
Thomas Lönngren
Executive Director

(Signature on file)

European Medicines Agency

Doc. Ref. EMEA/PDCO/26380/2009
EMEA-000290-PIP01-08

OPINION OF THE PAEDIATRIC COMMITTEE ON THE AGREEMENT OF A PAEDIATRIC INVESTIGATION PLAN AND A DEFERRAL AND A WAIVER

Scope of the application

Active substance:
Nilotinib

Invented name:
Tasigna

Condition(s):
Chronic myeloid leukaemia
Gastro-intestinal stromal tumour

Pharmaceutical form(s):
Hard capsule

Route(s) of administration:
Oral use

Name/corporate name of the PIP applicant:
Novartis Europharm Limited

Information about the authorised medicinal product:
See Annex II

Basis for opinion

Pursuant to of Regulation (EC) No 1901/2006 as amended, Novartis Europharm Limited submitted for agreement to the EMEA on 27 May 2008 an application for a paediatric investigation plan for the above mentioned medicinal product and a deferral under Article 20 of said Regulation and a waiver under Article 13 of said Regulation.

The procedure started on 1 July 2008.

Supplementary information was provided by the applicant on 27 November 2008.

7 Westferry Circus, Canary Wharf, London, E14 4HB, UK
Tel. (44-20) 74 18 84 00 Fax (44-20) 74 18 86 70
E-mail: mail@emea.europa.eu http://www.emea.europa.eu

Opinion

1. The Paediatric Committee, having assessed the proposed paediatric investigation plan in accordance with Article 17 of Regulation (EC) No 1901/2006 as amended, recommends as set out in the appended summary report:

- to agree the paediatric investigation plan in accordance with Article 18 of said Regulation,

- to grant a deferral in accordance with Article 21 of said Regulation,

- to grant a waiver for one or more subsets of the paediatric population in accordance with Article 13 of said Regulation and concluded in accordance with Article 11(1)(c) of said Regulation, on the grounds that the specific medicinal product does not represent a significant therapeutic benefit over existing treatments for paediatric patients.

The Icelandic and the Norwegian Paediatric Committee members agree with the above-mentioned recommendation of the Paediatric Committee.

2. The measures and timelines of the agreed paediatric investigation plan and the subset(s) of the paediatric population and condition(s) covered by the waiver are set out in the Annex I.

This opinion is forwarded to the applicant and the Executive Director of the Agency, together with its annex(es) and appendix.

London, 6 February 2009

On behalf of the Paediatric Committee
Dr Daniel Brasseur, Chairman

(Signature on file)

ANNEX I

THE MEASURES AND TIMELINES OF THE AGREED PAEDIATRIC INVESTIGATION PLAN AND THE SUBSET(S) OF THE PAEDIATRIC POPULATION AND CONDITION(S) COVERED BY THE WAIVER

A. CONDITION(S)

Chronic myeloid leukaemia
Gastro-intestinal stromal tumour

B. WAIVER

Gastro-intestinal stromal tumour

- **Condition**

The waiver applies to:

- All subsets of the paediatric population from birth to less than 18 years of age,

on the grounds that the specific medicinal product does not represent a significant therapeutic benefit as clinical studies(s) are not feasible.

C. PAEDIATRIC INVESTIGATION PLAN

- **Condition to be investigated**

Chronic myeloid leukaemia

- **Proposed PIP indication**

Treatment of Philadelphia chromosome-positive chronic myeloid leukaemia

- **Subset(s) of the paediatric population concerned by the paediatric development**

From birth to less than 18 years

- **Formulation(s)**

Capsule, 200 mg and 50 mg, unmanipulated or contents dispersed with yoghurt or applesauce, oral use

- **Studies**

Area	Number of studies	Description
Quality		Not applicable
Non-clinical	1	Oral (gavage) juvenile development study in rats
Clinical	3	Randomized, open-label, three-period crossover study comparing the bioavailability of nilotinib when administered as intact capsule or the capsule content mixed with yogurt or apple sauce in adult healthy volunteers Multiple-dose, open-label, single-agent, non-controlled trial to evaluate pharmacokinetics, pharmacodynamics, safety and activity in paediatric patients from birth to less than 18 years with Philadelphia chromosome-positive chronic myeloid leukaemia in chronic or accelerated phase who

		are imatinib-intolerant or in whom the disease is imatinib-resistant, or with refractory or relapsed Philadelphia chromosome-positive acute lymphoblastic leukaemia. Multiple-dose, open-label, single-agent, non-controlled, multi-centre trial to evaluate pharmacokinetics, safety and activity in paediatric patients from birth to less than 18 years with Philadelphia chromosome-positive chronic myeloid leukaemia in chronic or accelerated phase who are imatinib-intolerant or in whom the disease is imatinib-resistant or with newly diagnosed Philadelphia chromosome-positive chronic myeloid leukaemia in chronic phase.

Measures to address long term follow-up of potential safety issues and efficacy in relation to paediatric use:	Yes
Date of completion of the paediatric investigation plan:	By September 2015
Deferral for some or all studies contained in the paediatric investigation plan:	Yes

ANNEX II

INFORMATION ABOUT THE AUTHORISED MEDICINAL PRODUCT

EU Number	Invented name	Strength	Pharmaceutical Form	Route of administration	Packaging	Content (concentration)	Package size
EU/1/07/422/001	Tasigna	200 mg	Capsule, hard	Oral use	Blister (PVC/PVDC/Al)		28 capsules
EU/1/07/422/002	Tasigna	200 mg	Capsule, hard	Oral use	Blister (PA/Al/PVC/Al)		28 capsules
EU/1/07/422/003	Tasigna	200 mg	Capsule, hard	Oral use	Blister (PVC/PVDC/Al)		112 capsules
EU/1/07/422/004	Tasigna	200 mg	Capsule, hard	Oral use	Blister (PA/Al/PVC/Al)		112 capsules